A Case Report of Three Guillain-Barré Syndrome During SARS-CoV-2 Pandemic: Promising Outcome in a Patient with History of Multiple Sclerosis

AmirAli Ghahremani; Amir Bigdeli; Davoud Salarbashi; Pouyan Shakouri; Sepideh Elyasi

doi:10.18502/jpc.v10i3.10800

AmirAli Ghahremani Department of Neurology, School of Medicine, North Khorasan University of Medical Sciences, Bojnord, Iran.
Amir Bigdeli Department of Nephrology, School of Medicine, North Khorasan University of Medical Sciences, Bojnord, Iran.
Davoud Salarbashi Nanomedicine Research Center, School of Medicine, Gonabad University of Medical Sciences, Gonabad University of Medical Sciences, Gonabad, Iran.
Pouyan Shakouri Student Research Committee, School of Medicine, North Khorasan University of Medical Sciences, Bojnord, Iran.
Sepideh Elyasi Department of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.

DOI: https://doi.org/10.18502/jpc.v10i3.10800

Keywords: Guillain–Barré Syndrome; COVID-19; Multiple Sclerosis

Abstract

Neurologic complications in patients with coronavirus disease 19 (COVID-19) are common particularly in hospitalized patients. Guillain–Barré syndrome (GBS) is a rare complication of COVID-19. Most patients with GBS and COVID-19 presented with progressive, ascending limb weakness evolving over one to four days. There are some reported cases of GBS, mostly in form of case reports or case series, and also a comprehensive review on this topic. However, none of these cases experienced multiple sclerosis (MS) as an underlying disease. So, in this manuscript we reported three cases of COVID-19 induced GBS; one of them with history of MS and promising outcome after receiving five sessions of plasmapheresis and corticosteroid therapy.